Welcome to our dedicated page for Curis SEC filings (Ticker: CRIS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Curis Inc. filings document the regulatory record of a biotechnology company focused on emavusertib (CA-4948) and related oncology-development activities. Form 8-K disclosures cover financial results, clinical and regulatory updates, material agreements, capital-structure matters and Nasdaq listing-compliance notices.
Proxy and other filings describe shareholder voting matters, authorized-share proposals, securities issuances tied to preferred stock and warrant instruments, equity incentive plans, executive compensation and governance procedures. The filing record also includes pro forma financial information related to the completed sale of the company’s interest in Curis Royalty, LLC.
Curis, Inc. reported that Nantahala Capital Management, LLC and its managers Wilmot B. Harkey and Daniel Mack may be deemed beneficial owners of 4,215,165 shares of Curis common stock as of March 31, 2026. The reported stake represents 9.99% of the outstanding class based on 39,978,693 shares outstanding reported in the issuer's Form 10-K filed March 24, 2026. The 4,215,165 shares include 2,215,165 shares that may be acquired within sixty days through the exercise of warrants. Nantahala and each manager report shared voting and dispositive power for the 4,215,165 shares; no sole voting or dispositive power is reported.
Curis, Inc. is holding a virtual annual stockholder meeting on May 19, 2026 at 11:00 a.m. Eastern Time to vote on key corporate matters. Stockholders will elect two Class III directors, cast an advisory vote on executive pay, and ratify PricewaterhouseCoopers LLP as independent auditor for 2026.
The company is also asking stockholders to approve an amendment to its Restated Certificate of Incorporation to increase the number of authorized shares of common stock and to allow a possible adjournment if additional proxies are needed for that proposal. Stockholders of record at the close of business on March 23, 2026, when 39,978,693 common shares were outstanding, may vote online, by phone, by mail, or during the virtual meeting.
The proxy statement details board structure, committee responsibilities, and governance practices, including fully independent audit, compensation, and nominating committees. It also outlines environmental, social, and human capital initiatives, and discloses beneficial ownership, with several institutional investors each reporting approximately 9.99% beneficial stakes, subject to warrant-based beneficial ownership limitations.
Curis, Inc. will hold its 2026 annual meeting of stockholders virtually on May 19, 2026 to elect two Class III directors and approve several proposals, including an Authorized Shares Proposal to increase the number of authorized shares of common stock. The record date for voting is March 23, 2026, and 39,978,693 shares were outstanding on that date.
The board recommends votes FOR all proposals, including the proposed amendment to the Restated Certificate of Incorporation to increase authorized shares and a non-binding advisory vote on executive compensation. The proxy materials will be mailed or emailed in April 2026 and shareholders may vote online, by phone, by mail, or during the virtual meeting.
Curis, Inc. ownership disclosure: Nantahala Capital Management, LLC and its managers report beneficial ownership of 4,215,165 shares of Curis Common Stock as of March 31, 2026. Each of the reporting persons — Nantahala, Wilmot B. Harkey and Daniel Mack — is shown as beneficial owner of 9.99% of the class based on a cited 2,215,165 shares outstanding figure from a Form 10-K filed March 27, 2026. The filing states the shares are held by funds and separately managed accounts under Nantahala’s control and that Nantahala and the two managers have shared voting and dispositive power over the 4,215,165 shares.
CURIS, INC.: Nantahala Capital Partners LP reported beneficial ownership of 2,944,000 shares of Common Stock as of March 31, 2026. This holding represents 6.98% of the class, based on 39,978,693 shares outstanding as of March 27, 2026. The reported total includes 2,208,000 shares exercisable within sixty days.
Curis Inc. director Kenneth I. Kaitin reported an open-market purchase of 10,000 shares of Curis common stock at $0.5487 per share. After this transaction, his direct ownership increased to 11,407 shares, indicating a meaningful addition relative to his prior holdings.
CURIS INC filed a Schedule 13G reporting a shared beneficial ownership position of 4,025,992 shares, equal to 9.9% of the outstanding common stock. The reporting persons are Stonepine Capital Management, LLC; Stonepine Capital, L.P.; Stonepine GP, LLC; and Jon M. Plexico, filing jointly.
The filing states the calculation is based on 39,978,693 shares outstanding as of March 20, 2026. It also discloses warrants to acquire 10,000,002 shares that are subject to a 9.99% beneficial ownership limitation. Voting and dispositive power are reported as shared for the 4,025,992 shares; sole voting/dispositive power is reported as 0 for each reporting person.
Curis, Inc. is a biotechnology company focused almost entirely on developing emavusertib (CA-4948), an oral IRAK4/FLT3 inhibitor for hematologic cancers including PCNSL, CLL and AML. Emavusertib has Orphan Drug Designation in the U.S. for PCNSL, AML and MDS, and in Europe for PCNSL.
The company highlights substantial financial strain. As of December 31, 2025, it held $5.1 million in cash and cash equivalents and subsequently raised about $18.6 million net in a January 2026 PIPE financing. Management states there is substantial doubt about Curis’s ability to continue as a going concern and that significant additional capital will be required to fund development and operations.
Curis may need equity financings, collaborations or strategic alternatives, including asset sales or a sale of the company, and acknowledges potential outcomes such as dissolution or bankruptcy if funding cannot be secured. In November 2025, it sold its Erivedge royalty entity, ending revenue from the Genentech collaboration. As of March 20, 2026, there were 39,978,693 common shares outstanding, and Curis also notes the risk of Nasdaq delisting if listing standards are not maintained.
CURIS INC CDO Jonathan B. Zung converted preferred stock into common shares. On March 20, 2026, he converted 50 shares of Series B Convertible Preferred Stock into 66,667 shares of common stock for no additional cash consideration. Following the conversion, he holds 66,667 common shares directly.